• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. Its uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott and Steven Shak in August 2000 and is headquartered in Redwood City, CA.
| Market Cap | 2.366 Billion | Shares Outstanding | 37.29 Million | Avg 30-day Volume | 1.072 Million |
| P/E Ratio | 46.689 | Dividend Yield | 0.0 | EPS | 1.28 |
| Price to Revenue | 5.9794 | Debt to Equity | 0.0 | EBITDA | 67.999 Million |
| Price to Book Value | 7.5625 | Operating Margin | 12.5622 | Enterprise Value | 2.367 Billion |
| Current Ratio | 5.959 | EPS Growth | 2.02 | Quick Ratio | 5.722 |
| 1 Yr BETA | 1.2543 | 52-week High/Low | 0.0 / | Profit Margin | 12.8068 |
| Operating Cash Flow Growth | 49.6302 | Altman Z-Score | 15.8039 | Free Cash Flow to Firm | 43.147 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
100 | 2019-11-08 | 0 | |
|
No longer subject to file | 2019-11-08 | 0 | |
|
No longer subject to file | 2019-11-08 | 0 | |
|
POPOVITS KIMBERLY J PRESIDENT AND CEO |
|
No longer subject to file | 2019-11-08 | 0 |
|
SHAK STEVEN CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
COLE G BRADLEY CFO |
|
No longer subject to file | 2019-11-08 | 0 |
|
No longer subject to file | 2019-11-08 | 0 | |
|
No longer subject to file | 2019-11-08 | 0 | |
|
No longer subject to file | 2019-11-08 | 0 | |
|
PLA FREDERIC COO |
|
No longer subject to file | 2019-11-08 | 0 |
|
LEBER LAURA CHIEF COMMUNICATION OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
MCEACHRON KIM CHIEF PEOPLE OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
RADFORD JASON W. CHIEF LEGAL OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
VAUGHN JAMES J CHIEF COMMERCIAL OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
HOOF TORSTEN CHIEF INT'L COMMERCIAL OFFICER |
|
No longer subject to file | 2019-11-08 | 0 |
|
9,430,119 | 2019-10-01 | 0 | |
|
BAKER BROS. INVESTMENTS II, L.P. |
|
9,471,630 | 2019-08-29 | 0 |
|
BAKER BROTHERS LIFE SCIENCES LP BAKER BROS. INVESTMENTS II, L.P. BAKER BROTHERS LIFE SCIENCES LP |
|
13,494,075 | 2018-11-16 | 0 |
|
FEBBO PHILLIP G. CHIEF MEDICAL OFFICER |
|
21,387 | 2018-02-20 | 0 |
|
0 | 2016-06-10 | 0 | |
|
59,653 | 2014-10-01 | 0 | |
|
SCHORNO DEAN L CFO |
|
51,825 | 2014-06-10 | 0 |
|
HIBBS KATHY L SVP & GENERAL COUNSEL |
|
15,787 | 2014-02-15 | 0 |
|
3,880 | 2013-10-01 | 0 | |
|
0 | 2013-07-01 | 0 | |
|
BAKER BROS. INVESTMENTS II, L.P. |
|
16,500 | 2013-06-07 | 0 |
|
13,273,646 | 2013-06-04 | 0 | |
|
BAKER BROS. INVESTMENTS II, L.P. |
|
12,537,654 | 2013-01-01 | 0 |
|
11,377,773 | 2012-10-01 | 0 | |
|
9,086,690 | 2012-07-26 | 0 | |
|
173,897 | 2012-07-26 | 0 | |
|
13,238 | 2012-07-26 | 0 | |
|
173,897 | 2012-07-26 | 0 | |
|
194,161 | 2012-07-26 | 0 | |
|
247,063 | 2012-07-26 | 0 | |
|
1,488,539 | 2012-07-26 | 0 | |
|
SCOTT RANDAL W CEO, INVITAE CORPORATION* |
|
2,400,998 | 2012-07-10 | 0 |
|
0 | 2012-06-08 | 0 | |
|
9,333,753 | 2012-05-21 | 0 | |
|
0 | 2012-04-12 | 0 | |
|
1,484,977 | 2012-03-07 | 0 | |
|
8,255,421 | 2012-03-07 | 0 | |
|
227,840 | 2012-03-07 | 0 | |
|
BAKER JOFFRE CHIEF SCIENTIFIC OFFICER |
|
235,302 | 2012-02-15 | 0 |
|
187,135 | 2011-06-30 | 0 | |
|
24,357 | 2011-04-01 | 0 | |
|
194,161 | 2009-05-20 | 0 | |
|
GOLDBERG MICHAEL D |
|
8,250 | 2007-06-13 | 0 |
|
544,384 | 2007-03-01 | 0 | |
|
189,965 | 2007-03-01 | 0 | |
|
190,578 | 2007-03-01 | 0 | |
|
1,569,539 | 2007-03-01 | 0 | |
|
33,092 | 2007-03-01 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
